Guangdong Hybribio Biotech Co (SZSE:300639) Change In Receivables : ¥0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Guangdong Hybribio Biotech Co Change In Receivables?

Guangdong Hybribio Biotech Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0.0 Mil. It means Guangdong Hybribio Biotech Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Guangdong Hybribio Biotech Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥873.5 Mil. It means Guangdong Hybribio Biotech Co's Accounts Receivable declined by ¥873.5 Mil from Dec. 2022 to Dec. 2023 .

Guangdong Hybribio Biotech Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥1,830.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Guangdong Hybribio Biotech Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 912.45.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Guangdong Hybribio Biotech Co's liquidation value for the three months ended in Mar. 2024 was ¥1,857.6 Mil.

Guangdong Hybribio Biotech Co Change In Receivables Historical Data

The historical data trend for Guangdong Hybribio Biotech Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangdong Hybribio Biotech Co Change In Receivables Chart

Guangdong Hybribio Biotech Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-71.01

-275.72

-648.08

-1,919.96

873.52

Guangdong Hybribio Biotech Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Guangdong Hybribio Biotech Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.0 Mil.

Guangdong Hybribio Biotech Co (SZSE:300639) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Guangdong Hybribio Biotech Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1830.912	/	183.101	*	91
=	912.45

2. In Ben Graham's calculation of liquidation value, Guangdong Hybribio Biotech Co's accounts receivable are only considered to be worth 75% of book value:

Guangdong Hybribio Biotech Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	920.297	-	484.263	+	0.75 * 1830.912	+	0.5 * 96.838
=	1,857.6

Guangdong Hybribio Biotech Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Guangdong Hybribio Biotech Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Guangdong Hybribio Biotech Co (SZSE:300639) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangdong Hybribio Biotech Co Ltd (SZSE:300639) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

D 5-3-3-4, North High-tech Zone, Economic Development Zone, Chaozhou City, CHN, 521000

Website

http://www.hybribio.cn

Guangdong Hybribio Biotech Co Ltd is a Chinese company engaged in offering vitro diagnostic assays. Its products include in-vitro diagnostic kits, female sample collection kit, DNA extraction kit, and other devices. The company's products help in the infectious pathogens detection and genetic disease detection, including human papillomavirus, thalassemia, G6PD, hearing loss susceptibility, phenylketonuria, and early cancer detection, among others. The company has a business presence in China and various other countries.

Guangdong Hybribio Biotech Co (SZSE:300639) Headlines

No Headlines